Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial

Overview of attention for article published in The Lancet, April 2019

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (89th percentile)

Mentioned by

news: 14 news outlets
blogs: 2 blogs
policy: 1 policy source
twitter: 174 X users
patent: 21 patents
facebook: 1 Facebook page

wikipedia: 1 Wikipedia page
f1000: 1 research highlight platform
guideline: 1 clinical guideline source
bluesky: 1 Bluesky user
podcasts: 1 podcast

Readers on

mendeley: 436 Mendeley

So far, Altmetric has seen 230 X posts from 174 X users, with an upper bound of 1,378,934 followers.

RT @CristinaDeReins: 5/ Pilots can't predict everything, but can reduce the surprise 📍The RADAR pilot successfully defined the optimal at…

5/ Pilots can't predict everything, but can reduce the surprise 📍The RADAR pilot successfully defined the optimal atrasentan dose to ⬇️ albuminuria without fluid retention https://t.co/IxfZctsgAh 📍Yet, SONAR trial still faced lower-than-expected eve…

@amitksvs References here: CREDENCE: https://t.co/HKhHT9kFqp FIDELIO-DKD: https://t.co/dXu1ZlqTjM SONAR: https://t.co/ELyfrCc3cD FLOW: https://t.co/qTVwBT392F

Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial - The Lancet https://t.co/FQSSXkaviI

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 226 additional X posts.